CXCL10/IP-10/CRG-2 Antibody (134013)

Recombinant Mouse CXCL10/CRG‑2 (Catalog # 466-CR) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CXCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse CXCL10/CRG‑2 (0.5 µg/mL) is neutralized (green line) by increasing concentrations of Mouse CXCL10/CRG‑2 Monoclonal Antibody (Catalog # MAB466). The ND50 is typically 10-40 µg/mL.

• Reactivity: Mu
• Applications: WB, B/N, ELISA(Cap)
• Clone: 134013
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

CXCL10/IP-10/CRG-2 Antibody (134013) Summary

• Immunogen: E. coli-derived recombinant mouse CXCL10/IP-10/CRG-2
  Ile22-Pro98
  Accession # P17515
• Specificity: Detects mouse CXCL10/IP-10/CRG-2 in ELISAs and Western blots. In Western blots, this antibody does not cross-react with recombinant human (rh) CXCL1, 2, 3, 5, 6, 7, 9, 10, 11, 12/SDF-1 alpha, 12/SDF-1 beta, 13, rmCXCL1, 2, 6, 9, 11, 12/SDF-1 alpha, 13, rpCXCL8, rrCXCL1, 3/CINC-2 alpha, 3/CINC-2 beta
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: Cxcl10
• Purity: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Western Blot 1 ug/mL
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • Neutralization 10-40 ug/mL
  • ELISA Standard (Matched Pair)
• Application Notes: ELISA Detection: Mouse CXCL10/IP-10/CRG-2 Biotinylated Antibody (Catalog number BAF466)
  Standard: Recombinant Mouse CXCL10/IP-10/CRG-2 (Catalog number 466-CR)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Purity: Protein A or G purified from hybridoma culture supernatant
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL10/IP-10/CRG-2 Antibody (134013)

• C7
• chemokine (C-X-C motif) ligand 10
• CRG2
• CRG-2
• CXCL10
• gIP-10
• IFI10
• INP10
• IP-10
• mob-1
• SCYB10

Background

The gene for CRG-2, a mouse homolog of human IP-10, was originally identified as an immediate early gene induced in response to macrophage activation. It has since been shown that CRG-2 mRNA is induced by alpha / beta / gamma -interferons and by lipopolysaccharide in macrophages, astrocytes and microglia. Human IP-10 was also shown to be expressed in activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. Mouse CRG-2 cDNA encodes a 98 amino acid (aa) residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted mature protein. Mature CRG-2 shares approximately 67% amino acid sequence identity with human IP-10. The amino acid sequence of CRG-2 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CRG-2 has been shown to be a chemoattractant for activated T-lymphocytes. Recently, human IP-10 has also been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent anti-tumor effect. A chemokine receptor specific for IP-10 and MIG (CXCR3) has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.

1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
2. Vanguri, P. (1996) J. Neuroimmunol. 56:35.
3. Sgadari, C. et al. (1996) Blood, 87:3877.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL10/IP-10/CRG-2 Antibody (MAB466)(6)

Publications using MAB466

• M William, LP Leroux, V Chaparro, TE Graber, T Alain, M Jaramillo Translational repression of Ccl5 and Cxcl10 by 4E-BP1 and 4E-BP2 restrains the ability of mouse macrophages to induce migration of activated T�cells Eur. J. Immunol., 2019;0(0):. 2019 [PMID: 31032899] (Neutralization, Mouse)
• AK Verma, TS Waghmare, GR Jachak, SC Philkhana, DS Reddy, A Basu Nitrosporeusine analogue ameliorates Chandipura virus induced inflammatory response in CNS via NF?b inactivation in microglia PLoS Negl Trop Dis, 2018;12(7):e0006648. 2018 [PMID: 30001342] (ELISA Development (Capture), Mouse)
• R Lv, J Zhao, M Lei, D Xiao, Y Yu, J Xie IL-33 Attenuates Sepsis by Inhibiting IL-17 Receptor Signaling through Upregulation of SOCS3 Cell. Physiol. Biochem., 2017;42(5):1961-1972. 2017 [PMID: 28793286] (ELISA Development (Capture), Mouse)
• Ioannidis L, Nie C, Ly A, Ryg-Cornejo V, Chiu C, Hansen D Monocyte- and Neutrophil-Derived CXCL10 Impairs Efficient Control of Blood-Stage Malaria Infection and Promotes Severe Disease. J Immunol, 2015;196(3):1227-38. 2015 [PMID: 26718341] (ELISA Development (Capture), Mouse)
• Barreira da Silva R, Laird M, Yatim N, Fiette L, Ingersoll M, Albert M Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol, 2015;16(8):850-8. 2015 [PMID: 26075911] (Neutralization, Mouse)
• Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T, Takami T Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol., 2008;83(5):1136-44. 2008 [PMID: 18285406] (Flow Cytometry, Mouse)

Bioinformatics

• Gene Symbol: Cxcl10
• Uniprot:
  • P17515()